Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Public ClinicalTrials.gov record NCT00569673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Docetaxel (NSC #628503) Plus Trabectedin (Yondelis®), R279741, IND # 101018) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy, such as docetaxel and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF and pegfilgrastim, may help the immune system recover from the side effects of chemotherapy. Giving combination chemotherapy together with G-CSF or pegfilgrastim may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving docetaxel and trabectedin together with G-CSF or pegfilgrastim works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Study identification
- NCT ID
- NCT00569673
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 71 participants
Conditions and interventions
Interventions
- filgrastim Biological
- pegfilgrastim Biological
- docetaxel Drug
- trabectedin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Jan 2012 (Actual)
- Completion
- Not listed
- Last update posted
- Jul 18, 2018
Started 2008
United States locations
- U.S. sites
- 37
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Saint Joseph Medical Center - Burbank | Burbank | California | 91505 | — |
| Jonsson Comprehensive Cancer Center at UCLA | Los Angeles | California | 90095-1781 | — |
| George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus | New Britain | Connecticut | 06050 | — |
| Tunnell Cancer Center at Beebe Medical Center | Lewes | Delaware | 19958 | — |
| CCOP - Christiana Care Health Services | Newark | Delaware | 19713 | — |
| Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center | Savannah | Georgia | 31403-3089 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Hinsdale Hematology Oncology Associates | Hinsdale | Illinois | 60521 | — |
| St. Vincent Indianapolis Hospital | Indianapolis | Indiana | 46260 | — |
| Union Hospital Cancer Program at Union Hospital | Elkton | Maryland | 21921 | — |
| UMASS Memorial Cancer Center - University Campus | Worcester | Massachusetts | 01655 | — |
| St. John's Regional Health Center | Springfield | Missouri | 65804 | — |
| Hulston Cancer Center at Cox Medical Center South | Springfield | Missouri | 65807 | — |
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | St Louis | Missouri | 63110 | — |
| Cancer Institute of New Jersey at Cooper - Voorhees | Voorhees Township | New Jersey | 08043 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87131-5636 | — |
| Alamance Cancer Center at Alamance Regional Medical Center | Burlington | North Carolina | 27216 | — |
| Blumenthal Cancer Center at Carolinas Medical Center | Charlotte | North Carolina | 28232-2861 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| MetroHealth Cancer Care Center at MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Cleveland Clinic Cancer Center at Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center | Columbus | Ohio | 43210-1240 | — |
| Riverside Methodist Hospital Cancer Care | Columbus | Ohio | 43214-3998 | — |
| Mount Carmel Health - West Hospital | Columbus | Ohio | 43222 | — |
| David L. Rike Cancer Center at Miami Valley Hospital | Dayton | Ohio | 45409 | — |
| Hillcrest Cancer Center at Hillcrest Hospital | Mayfield Heights | Ohio | 44124 | — |
| Lake/University Ireland Cancer Center | Mentor | Ohio | 44060 | — |
| Oklahoma University Cancer Institute | Oklahoma City | Oklahoma | 73104 | — |
| Rosenfeld Cancer Center at Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104-4283 | — |
| UPMC Cancer Center at Magee-Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Women and Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Huntsman Cancer Institute at University of Utah | Salt Lake City | Utah | 84112 | — |
| Carilion Gynecologic Oncology Associates | Roanoke | Virginia | 24014 | — |
| University of Wisconsin Paul P. Carbone Comprehensive Cancer Center | Madison | Wisconsin | 53792-6164 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00569673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2018 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00569673 live on ClinicalTrials.gov.